Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X

Find the latest Drugs in Development and Pipeline Prospector News of Bayer AG.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Bayer AG
Germany Flag
Country
Country
Germany
Address
Address
Mullerstr. 178, 13353 Berlin
Telephone
Telephone
+49 30 468 1111
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

VVD-130037 is the investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, which is investigated for the treatment of advanced solid tumors.


Lead Product(s): VVD-130037

Therapeutic Area: Oncology Product Name: VVD-130037

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Vividion Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Kerendia/Firialta (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to block harmful effects of MR overactivation and expands clinical development program investigating finerenone for potential treatment of heart failure.


Lead Product(s): Finerenone

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Kerendia

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to block harmful effects of MR overactivation, which is investigating for the treatment of heart failure.


Lead Product(s): Finerenone

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Kerendia

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: CPC Clinical Research

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Bayer will provide Nubeqa to Celcuity for its Phase 1b/2 trial of PKI-587 (gedatolisib), a potent inhibitor that selectively targets all Class I isoforms of PI3K and mTOR, in combination with darolutamide in metastatic castration resistant prostate cancer.


Lead Product(s): Gedatolisib,Darolutamide

Therapeutic Area: Oncology Product Name: PF-05212384

Highest Development Status: IND EnablingProduct Type: Small molecule

Recipient: Celcuity

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 22, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Eylea HD(aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor approved in 8mg dose for the treatment of neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.


Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology Product Name: Eylea HD

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: Regeneron Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

AB-1003 (also known as LION-101) is a novel investigational recombinant adeno-associated virus based gene therapy currently being developed as a one-time intravenous infusion for the treatment of patients with LGMD type 2I/R9.


Lead Product(s): AB-1003

Therapeutic Area: Genetic Disease Product Name: AB-1003

Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The partnership aims to jointly develop emodepside, an anthelmintic substance that is effective against several gastrointestinal nematodes in domestic animals, in the clinical development for treating humans infected with soil-transmitted helminths.


Lead Product(s): Emodepside

Therapeutic Area: Infections and Infectious Diseases Product Name: BAY 44-4400

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Swiss TPH

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 20, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, NorthStar will provide Bayer with its environmentally preferred, non-carrier added Ac-225. NorthStar’s Ac-225 will be used by Bayer for several of its radiopharmaceutical programs, including Actinium-225 conjugated Therapies.


Lead Product(s): Actinium-225 Conjugated Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Undisclosed

Recipient: NorthStar Medical Radioisotopes

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Bayer and Peking University will advance research into drug discovery and development, while accelerating scientific research on cutting-edge technologies, with the focus on selected key areas of interests, such as oncology, cardiorenal, immunology and cell and gene therapy.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Undisclosed

Recipient: Peking University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The partnership aims for the development of multiple clinical candidates including, BAY401016, a mAb targeting the protein Semaphorin-3A, is being developed in phase I study as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease.


Lead Product(s): BAY401016

Therapeutic Area: Genetic Disease Product Name: BAY401016

Highest Development Status: Phase IProduct Type: Large molecule

Recipient: Evotec

Deal Size: $351.3 million Upfront Cash: Undisclosed

Deal Type: Collaboration June 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY